Financials Takeda Pharmaceutical Company Limited

Equities

4502

JP3463000004

Pharmaceuticals

Delayed Japan Exchange 20:10:23 2024-06-24 EDT 5-day change 1st Jan Change
4,147 JPY +1.27% Intraday chart for Takeda Pharmaceutical Company Limited -0.46% +2.32%

Valuation

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 7,029,161 5,153,364 6,229,971 5,423,454 6,762,204 6,424,784 - -
Enterprise Value (EV) 1 12,054,743 9,609,054 9,862,522 8,919,170 10,611,015 10,950,330 10,613,297 10,274,267
P/E ratio 40 x 118 x 16.6 x 23.8 x 21.3 x 45.4 x 70.7 x 29.4 x
Yield 3.98% 5.44% 4.52% 5.15% 4.14% 4.49% 4.76% 4.86%
Capitalization / Revenue 3.35 x 1.57 x 1.95 x 1.52 x 1.68 x 1.54 x 1.5 x 1.48 x
EV / Revenue 5.75 x 2.92 x 3.08 x 2.5 x 2.63 x 2.57 x 2.48 x 2.36 x
EV / EBITDA 25.3 x 14 x 9.23 x 8.54 x 9.19 x 11.6 x 9.66 x 8.79 x
EV / FCF -4.81 x 9.99 x 16 x 8.92 x 28.7 x 43.4 x 15.6 x 15.6 x
FCF Yield -20.8% 10% 6.26% 11.2% 3.49% 2.31% 6.43% 6.42%
Price to Book 1.36 x 1.09 x 1.2 x 0.95 x 1.06 x 0.9 x 0.91 x 0.94 x
Nbr of stocks (in thousands) 1,554,780 1,557,849 1,563,355 1,550,444 1,554,530 1,568,934 - -
Reference price 2 4,521 3,308 3,985 3,498 4,350 4,095 4,095 4,095
Announcement Date 19-05-14 20-05-13 21-05-11 22-05-11 23-05-11 24-05-09 - -
1JPY in Million2JPY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 2,097,200 3,291,200 3,197,812 3,569,006 4,027,478 4,263,762 4,280,821 4,345,024
EBITDA 1 477,415 684,057 1,068,940 1,043,995 1,154,905 942,077 1,098,623 1,168,649
EBIT 1 205,000 100,400 509,269 460,844 490,505 214,100 279,494 418,182
Operating Margin 9.77% 3.05% 15.93% 12.91% 12.18% 5.02% 6.53% 9.62%
Earnings before Tax (EBT) 1 94,896 -60,754 366,235 302,571 375,090 52,791 98,258 291,187
Net income 1 109,100 44,200 376,005 230,059 317,017 144,067 92,573 220,440
Net margin 5.2% 1.34% 11.76% 6.45% 7.87% 3.38% 2.16% 5.07%
EPS 2 113.0 28.00 240.7 147.1 204.3 92.09 57.96 139.1
Free Cash Flow 1 -2,507,219 961,871 617,401 999,853 370,054 252,482 682,369 659,391
FCF margin -119.55% 29.23% 19.31% 28.01% 9.19% 5.92% 15.94% 15.18%
FCF Conversion (EBITDA) - 140.61% 57.76% 95.77% 32.04% 26.8% 62.11% 56.42%
FCF Conversion (Net income) - 2,176.18% 164.2% 434.61% 116.73% 175.25% 737.11% 299.12%
Dividend per Share 2 180.0 180.0 180.0 180.0 180.0 188.0 194.8 199.1
Announcement Date 19-05-14 20-05-13 21-05-11 22-05-11 23-05-11 24-05-09 - -
1JPY in Million2JPY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2020 S1 2020 S2 2021 S1 2022 Q2 2022 S1 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 S1 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 S1 2024 Q3 2024 Q4 2025 Q1 2025 Q2 2025 S1 2025 Q3 2025 Q4 2026 S1
Net sales 1 1,660,200 1,631,000 1,590,785 844,797 1,794,400 901,294 873,289 972,465 1,002,340 1,974,800 1,096,551 956,200 1,058,618 1,043,089 2,101,707 1,111,200 1,050,869 1,073,112 1,080,400 2,126,400 1,139,257 1,062,529 2,137,000
EBITDA 1 - - - - - - - - - - - 249,972 340,072 133,355 - 291,975 176,675 320,925 282,725 - 368,925 202,525 -
EBIT 1 50,300 50,100 215,588 97,448 346,000 116,484 -1,619 150,515 104,485 255,000 146,990 88,600 168,571 -49,341 119,230 104,900 -10,055 87,880 73,125 137,550 74,350 29,175 239,500
Operating Margin 3.03% 3.07% 13.55% 11.54% 19.28% 12.92% -0.19% 15.48% 10.42% 12.91% 13.4% 9.27% 15.92% -4.73% 5.67% 9.44% -0.96% 8.19% 6.77% 6.47% 6.53% 2.75% 11.21%
Earnings before Tax (EBT) 1 -27,557 -33,197 125,561 61,447 284,425 72,193 -54,047 155,473 64,549 220,022 107,153 47,900 135,033 -95,980 39,053 61,300 -47,500 60,840 44,187 57,650 35,554 -8,513 156,500
Net income 1 33,200 11,000 86,548 -16,778 183,600 57,769 -11,358 105,014 61,786 166,800 119,127 31,100 89,395 -48,030 41,365 105,700 -3,000 54,116 40,154 59,800 33,654 -2,013 120,500
Net margin 2% 0.67% 5.44% -1.99% 10.23% 6.41% -1.3% 10.8% 6.16% 8.45% 10.86% 3.25% 8.44% -4.6% 1.97% 9.51% -0.29% 5.04% 3.72% 2.81% 2.95% -0.19% 5.64%
EPS 2 21.00 - 55.45 -10.27 117.0 37.01 -6.950 67.94 40.06 108.0 76.70 20.03 57.51 -31.00 26.51 67.38 -1.920 32.13 23.80 47.50 24.35 -6.569 76.80
Dividend per Share 2 90.00 - 90.00 - 90.00 - - - - - - - - 94.00 94.00 - 94.00 - - - - - -
Announcement Date 19-10-31 20-05-13 20-10-29 21-10-28 21-10-28 22-02-03 22-05-11 22-07-28 22-10-27 22-10-27 23-02-02 23-05-11 23-07-27 23-10-26 23-10-26 24-02-01 24-05-09 - - - - - -
1JPY in Million2JPY
Estimates

Balance Sheet Analysis

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 5,025,582 4,455,690 3,632,551 3,495,716 3,848,811 4,385,952 4,188,513 3,849,483
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 10.53 x 6.514 x 3.398 x 3.348 x 3.333 x 4.656 x 3.813 x 3.294 x
Free Cash Flow 1 -2,507,219 961,871 617,401 999,853 370,054 252,482 682,369 659,391
ROE (net income / shareholders' equity) 3% 0.9% 7.6% 4.2% 5.3% 2.1% 1.35% 3.17%
ROA (Net income/ Total Assets) 1.06% -0.46% 2.85% 2.32% 2.76% 0.36% 0.82% 1.75%
Assets 1 10,334,963 -9,710,018 13,209,937 9,918,859 11,467,260 39,661,656 11,294,951 12,589,405
Book Value Per Share 2 3,319 3,032 3,309 3,666 4,087 4,636 4,503 4,338
Cash Flow per Share 2 397.0 403.0 599.0 520.0 632.0 557.0 655.0 648.0
Capex 1 134,114 217,710 236,468 186,037 633,689 480,730 646,300 291,364
Capex / Sales 6.39% 6.61% 7.39% 5.21% 15.73% 11.27% 15.1% 6.71%
Announcement Date 19-05-14 20-05-13 21-05-11 22-05-11 23-05-11 24-05-09 - -
1JPY in Million2JPY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
4,095 JPY
Average target price
4,744 JPY
Spread / Average Target
+15.86%
Consensus
  1. Stock Market
  2. Equities
  3. 4502 Stock
  4. Financials Takeda Pharmaceutical Company Limited